Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens.
Loading...
Issue Date
5/24/2024
Authors
Lodise, Thomas P
Kaye, Keith S
Santerre Henriksen, Anne
Kahlmeter, Gunnar
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
Antimicrobial resistance in uropathogens commonly causing urinary tract infections (UTIs) is a growing problem internationally. Pivmecillinam, the oral prodrug of mecillinam, has been used for over 40 years, primarily in Northern Europe and Canada. It is recommended in several countries as a first-line agent for the treatment of uncomplicated UTIs (uUTIs) and is now approved in the United States. We performed a structured literature search to review the available evidence on susceptibility of common uUTI-causing uropathogens to mecillinam. Among 38 studies included in this literature review, susceptibility rates for to mecillinam-including resistant phenotypes such as extended-spectrum β-lactamase-producing -exceed 90% in most studies. High rates of susceptibility were also reported among many other uropathogens including spp., spp., and spp. In the current prescribing climate within the United States, pivmecillinam represents a viable first-line treatment option for patients with uUTI.
Citation
Lodise TP, Kaye KS, Santerre Henriksen A, Kahlmeter G. Review of the In Vitro Microbiological Activity of Mecillinam Against Common Uropathogens in Uncomplicated Urinary Tract Infection: Focus on Resistant Pathogens. Open Forum Infect Dis. 2024 May 24;11(6):ofae296. doi: 10.1093/ofid/ofae296. PMID: 38868308; PMCID: PMC11167674.
ACPHS Research Commons URI
Description
Click on the Resource Link to access the article (may not be free).